Company Profile
Updated: 27-OCT-09FAES FARMA S.A.
International public company
Maximo Aguirre 14, Lamiaco, Leioa, E-48940, Spain
()34 94 481 83 00, 34 94 481 83 23 fax, http://www.faes.es
Primary SIC: Pharmaceutical Preparations, Primary NAICS: Pharmaceutical Preparation Manufacturing
Description: Manufacturing: Head of a Group of Companies with interests in the manufacture and sale of pharmaceuticals including antibiotics, alimentary tract and metabolic agents, cardiovascular, central nervous system, dermatology, gastroenterology, musculoskeletal, bone metabolism and respiratory drugs; manufacture and sale of over-the-counter products including cosmetics, nutritional supplements and sanitary products; research and development
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Preparing For AzaSite Launch, Inspire Gets $75M Investment.
BIOWORLD Today; 11/3/2009; 1299 words; ...designed to enhance the lung's mucosal hydration and mucociliary...fast-track status in the U.S. and orphan drug status in both the U.S. and Europe. Oral bilastine...though Inspire and partner FAES Farma SA, of Madrid, Spain, amended...
Hikma signs licensing agreement with Faes Farma for anti-histamine Bilastine.
ADP News Middle East & Africa; 7/17/2009; 676 words; ...pharmaceutical company FAES FARMA SA (MCE: FAE) for the...Under the agreement, FAES FARMA grants exclusive rights...others between HIKMA and FAES for additional licensed...reinforces the company's position as the partner...
Faes Farma licenses Indian rights to bilastine to Merck Serono.
Pharma Marketletter; 3/23/2009; 550 words; Spanish drugmaker Faes Farma has licensed the rights to sell...Serono, the drugs unit of Germany's Merck KGaA. India is Asia's third-largest pharmaceutical market...European Union reference member state. Faes has assigned rights to bilastine...
FAES FARMA-Company Report.
M2 Presswire; 1/25/2009; 492 words; ...www.companiesandmarkets.com: FAES FARMA-Company Report(C)1994-2009...companiesandmarkets.com adds new report: FAES FARMA-Company Report Private Company...along with detail on the company's management team and its products...
Faes Farma to co-market new brand of Grunenthal[sup.1]s Balianca in Spain.
Pharma Marketletter; 11/10/2008; 283 words; Spanish drugmaker Faes Farma has entered a deal to co-market its own version of Grunenthal's contraceptive Balianca (chlormadinone/ethinyl estrogen) in its domestic market. The Faes Farma branded version of the drug will be called Belara.
Recent News Articles
- Faes Farma licenses Indian rights to bilastine to Merck Serono.
Pharma Marketletter - March 23, 2009 - Faes Farma to co-market new brand of Grunenthal[sup.1]s Balianca in Spain.
Pharma Marketletter - November 10, 2008 - Faes Farma reports high profit, low sales.(revenue report)(Financial report)(Brief article)
Pharma Marketletter - May 19, 2008 - Faes Farma's FY 2007 net profit dips 3%.(revenue report)(Financial report)(Brief article)
Pharma Marketletter - March 10, 2008
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning
